Leading the Charge
The Backbone of our Innovation
The Dova Board brings impressive experience to the table, bright minds from across the spectrum of relevant disciplines helping to illuminate the path forward for our pharmaceutical solutions.
Roger A. Jeffs
Joined Dova Board: May 2017
Roger Jeffs retired as President and co-CEO from United Therapeutics in 2016 after a successful 18-year tenure. Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as director of research, development, and medical, and served as its president and chief operating officer from 2001 to 2014. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of 6 products for rare diseases, and managed the commercial effort that lead to a >20% CAGR and $1.5B annual revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in “recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children”.
Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co where he held roles in clinical development. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.
Dr. Jeffs served on the Board of Directors for United Therapeutics from 2001-2016, and currently serves on the Boards of five public companies: Albireo Pharma, Axsome Therapeutics, Dova Pharmaceuticals, Sangamo Therapeutics and Axovant Sciences.